![]() |
Addicted to Nicotine Section V: Psychobiology of Nicotine Addiction
COMORBIDITY AND SMOKING
John R. Hughes, M.D. Introduction Increased initiation, decreased cessation, and increased nicotine dependence have been associated with several behavioral traits and disorders. These associations are often strong. Although the rates of current psychiatric disorders among smokers are small, more prevalent occurrence of simple psychological distress appears to undermine cessation. There are three possibilities for explaining this association: (1) Behavioral variables could be causing smoking changes, (2) smoking changes could be causing behavioral changes, or (3) some third variable could be associated with both the behavior and the smoking pattern. What We Know Causality can be estimated from epidemiological data by examining the consistency, strength, temporal precedence, dose-responsivity, and biological plausibility of any association. Using these criteria, major findings thus far are as follows:
In summary:
What We Need To Know More About First, several associations are debatable. Since the evidence is contradictory, large, generalizable studies are needed to determine whether smokers with a past history of alcoholism and depression have a more difficult time stopping smoking and whether smoking cessation can induce relapse to alcohol or other drug abuse or psychiatric disorders. Second, the probability that those smokers who find it easier to stop, eventually do, suggests that comorbidity may be even more prevalent among the remaining future smokers. We need survey data to determine whether comorbidity is increasing or decreasing over time. Third, we need to test existing hypotheses to account for comorbidity via experimental designs, including testing third variables that might account for associations. Replication will be important, as many hypotheses have one or two studies to support them, but no more. Until biological and behavioral mechanisms are elucidated, designing prevention treatment interventions for comorbid smokers will be difficult. The hypotheses that have the most evidence thus far, or are the more plausible, include the following:
Fourth, we need to know whether treatments for psychiatric comorbidity influence smoking. For example, generalizable experimental trials could replicate whether methadone increases smoking, clozapine decreases smoking, and haloperidol increases smoking. Fifth, we need to know whether treatments for smoking influence comorbidity. For example, generalizable experimental trials may show whether cessation increases or decreases drug use or sobriety in abusers of alcohol and other drugs, whether cessation precipitates relapse to depression, and so forth. The following questions should be answered:
Recommended Reading Fertig, J.B., and Allen, J.P. Anonymous Alcohol and Tobacco: From Basic Science to Clinical Practice. Washington, DC: Supt. of Docs., U.S. Govt. Print. Off., 1995. Glassman, A.H. Cigarette smoking: Implications for psychiatric illness. Am J Psychiatry 150:546-553, 1993. Lavin, M.R.; Siris, S.G.; and Mason, S.E. What is the clinical importance of cigarette smoking in schizophrenia? Am J Addict 5(3):189-208, 1996. |
NIDA Home | Site Map | Search | FAQs | Accessibility | Privacy | FOIA (NIH) | Employment | Print Version
|